Company: BIAF
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023405
Chunk: 2

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 2
---
5  
    2024 

    Net revenue 
    $1,446,066  
    $2,350,386  
    $4,569,146  
    $7,154,429 

    Operating expenses: 

    Direct costs and expenses 
     942,211  
     1,440,158  
     3,326,673  
     4,421,309 
  
    Research and development 
     330,589  
     274,497  
     1,009,347  
     1,070,569 
  
    Clinical development 
     143,311  
     93,705  
     410,943  
     194,127 
  
    Selling, general and administrative 
     2,209,441  
     2,364,592  
     6,876,551  
     7,023,311 
  
    Depreciation and amortization 
     113,360  
     151,298  
     381,177  
     452,005 

    Total operating expenses 
     3,738,912  
     4,324,250  
     12,004,691  
     13,161,321 

    Loss from operations 
     (2,292,846) 
     (1,973,864) 
     (7,435,545) 
     (6,006,892)

    Other income (expense): 

    Interest income 
     1,088  
     2,228  
     3,655  
     13,541 
  
    Interest expense 
     (5,358) 
     (21,631) 
     (31,303) 
     (67,430)
  
    Other income 
     513  
     9,683  
     38,568  
     9,683 
  
    Other expense 
     (3,839) 
     (14,697) 
     (496,524) 
     (10,186)
  
    Change in fair value of warrants issued 
     (2,747,460) 
     —  
     (3,810,278) 
     — 

    Total other